New analytical method helps in building largest cancer cell line sensitivity dataset to date

Small-molecule-sensitivity profiling of cancer cell lines (CCLs) has emerged as an approach to illuminate the mechanism of action of compounds and to launch the early stage of the discovery of new precision therapies. In a study in Cancer Discovery, a team of scientists from Broad Institute's Center for the Science of Therapeutics — led by researchers Stuart Schreiber, Paul Clemons, and Alykhan Shamji — presents the largest CCL sensitivity dataset to date, and an exciting new analysis method, termed “annotated cluster multi-dimensional enrichment” (ACME), integrating information from multiple CCLs and small molecules.